CN105567643A - 可分泌抗ev71病毒蛋白vp1单克隆抗体的杂交瘤细胞、单克隆抗体及应用 - Google Patents
可分泌抗ev71病毒蛋白vp1单克隆抗体的杂交瘤细胞、单克隆抗体及应用 Download PDFInfo
- Publication number
- CN105567643A CN105567643A CN201511005121.6A CN201511005121A CN105567643A CN 105567643 A CN105567643 A CN 105567643A CN 201511005121 A CN201511005121 A CN 201511005121A CN 105567643 A CN105567643 A CN 105567643A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- pad
- virus
- hybridoma
- viral protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 title claims abstract description 43
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 32
- 241000700605 Viruses Species 0.000 title abstract description 45
- 230000003248 secreting effect Effects 0.000 title abstract description 10
- 241001529459 Enterovirus A71 Species 0.000 claims abstract description 10
- 238000001514 detection method Methods 0.000 claims description 68
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 54
- 239000010931 gold Substances 0.000 claims description 43
- 229910052737 gold Inorganic materials 0.000 claims description 43
- 238000002360 preparation method Methods 0.000 claims description 38
- 239000000020 Nitrocellulose Substances 0.000 claims description 19
- 238000003745 diagnosis Methods 0.000 claims description 19
- 229920001220 nitrocellulos Polymers 0.000 claims description 19
- 238000010521 absorption reaction Methods 0.000 claims description 18
- 239000000084 colloidal system Substances 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 241001494479 Pecora Species 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 3
- 239000000427 antigen Substances 0.000 abstract description 13
- 108091007433 antigens Proteins 0.000 abstract description 13
- 102000036639 antigens Human genes 0.000 abstract description 13
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 239000002105 nanoparticle Substances 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract 1
- 101710197658 Capsid protein VP1 Proteins 0.000 description 34
- 101710132601 Capsid protein Proteins 0.000 description 33
- 101710108545 Viral protein 1 Proteins 0.000 description 33
- 239000000243 solution Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 21
- 239000007788 liquid Substances 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 206010003445 Ascites Diseases 0.000 description 11
- 239000012980 RPMI-1640 medium Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000005374 membrane filtration Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000030194 mouth disease Diseases 0.000 description 7
- 241000709661 Enterovirus Species 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000709687 Coxsackievirus Species 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 229910021505 gold(III) hydroxide Inorganic materials 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000024835 cytogamy Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000988559 Enterovirus A Species 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 2
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- SJUCACGNNJFHLB-UHFFFAOYSA-N O=C1N[ClH](=O)NC2=C1NC(=O)N2 Chemical compound O=C1N[ClH](=O)NC2=C1NC(=O)N2 SJUCACGNNJFHLB-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101710106388 Structural protein VP1 Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1009—Picornaviridae, e.g. hepatitis A virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511005121.6A CN105567643B (zh) | 2015-12-28 | 2015-12-28 | 可分泌抗ev71病毒蛋白vp1单克隆抗体的杂交瘤细胞、单克隆抗体及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511005121.6A CN105567643B (zh) | 2015-12-28 | 2015-12-28 | 可分泌抗ev71病毒蛋白vp1单克隆抗体的杂交瘤细胞、单克隆抗体及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105567643A true CN105567643A (zh) | 2016-05-11 |
CN105567643B CN105567643B (zh) | 2020-01-17 |
Family
ID=55878275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511005121.6A Active CN105567643B (zh) | 2015-12-28 | 2015-12-28 | 可分泌抗ev71病毒蛋白vp1单克隆抗体的杂交瘤细胞、单克隆抗体及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105567643B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106119209A (zh) * | 2016-07-01 | 2016-11-16 | 武汉爱博泰克生物科技有限公司 | 一种抗肠道病毒EV71 IgA单克隆抗体及应用 |
CN109917140A (zh) * | 2019-04-09 | 2019-06-21 | 潍坊市康华生物技术有限公司 | 一种柯萨奇病毒A6型和A10型IgM抗体联合检测的试剂条及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102243237A (zh) * | 2010-05-14 | 2011-11-16 | 北京贝尔生物工程有限公司 | 肠道病毒71型抗原检测试纸条(胶体金法) |
WO2013032404A1 (en) * | 2011-08-26 | 2013-03-07 | Temasek Life Sciences Laboratory Limited | Human enterovirus specific antibodies and their uses in diagnostics |
CN104407145A (zh) * | 2014-10-28 | 2015-03-11 | 绍兴市疾病预防控制中心 | 肠道病毒71型乳胶凝集检测试剂盒制备及应用 |
-
2015
- 2015-12-28 CN CN201511005121.6A patent/CN105567643B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102243237A (zh) * | 2010-05-14 | 2011-11-16 | 北京贝尔生物工程有限公司 | 肠道病毒71型抗原检测试纸条(胶体金法) |
WO2013032404A1 (en) * | 2011-08-26 | 2013-03-07 | Temasek Life Sciences Laboratory Limited | Human enterovirus specific antibodies and their uses in diagnostics |
CN103841993A (zh) * | 2011-08-26 | 2014-06-04 | 淡马锡生命科学实验室有限公司 | 人肠道病毒特异性抗体及其在诊断中的应用 |
CN104407145A (zh) * | 2014-10-28 | 2015-03-11 | 绍兴市疾病预防控制中心 | 肠道病毒71型乳胶凝集检测试剂盒制备及应用 |
Non-Patent Citations (4)
Title |
---|
伊瑶等: "抗肠道病毒EV71型外壳蛋白VPl单克隆抗体的制备和鉴定", 《中华实验和临床病毒学杂志》 * |
包林等: "肠道病毒71 型VP1蛋白单克隆抗体的制备及初步鉴定", 《南京医科大学学报(自然科学版)》 * |
吴菲菲等: "肠道病毒71 型特异性单克隆抗体的制备及其在病毒鉴定中的应用", 《东南大学学报》 * |
孙园园等: "pH 值对胶体金标记单克隆抗体性能的影响", 《细胞与分子免疫学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106119209A (zh) * | 2016-07-01 | 2016-11-16 | 武汉爱博泰克生物科技有限公司 | 一种抗肠道病毒EV71 IgA单克隆抗体及应用 |
CN106119209B (zh) * | 2016-07-01 | 2019-10-25 | 武汉爱博泰克生物科技有限公司 | 一种抗肠道病毒EV71 IgA单克隆抗体及应用 |
CN109917140A (zh) * | 2019-04-09 | 2019-06-21 | 潍坊市康华生物技术有限公司 | 一种柯萨奇病毒A6型和A10型IgM抗体联合检测的试剂条及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105567643B (zh) | 2020-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102747040B (zh) | 一种抗甲型流感病毒核蛋白单克隆抗体及其制备与应用 | |
CN103173420B (zh) | 可分泌抗心肌肌钙蛋白i单抗的杂交瘤细胞及应用 | |
CN104450625A (zh) | 可分泌抗疟原虫乳酸脱氢酶单克隆抗体的杂交瘤细胞、单克隆抗体及应用 | |
CN104357401A (zh) | 可分泌抗ii型登革病毒ns1单克隆抗体的杂交瘤细胞、单克隆抗体及应用 | |
CN102967710A (zh) | 小反刍兽疫抗体检测的竞争elisa试剂盒及其制备方法 | |
CN105859880B (zh) | 抗a型口蹄疫病毒中和性单克隆抗体及其应用 | |
CN101343319B (zh) | 抗登革病毒e蛋白的单克隆抗体、制备方法及其应用 | |
CN101717754A (zh) | 一种71型肠道病毒及其应用 | |
CN101519447A (zh) | 抗兔出血症病毒vp60蛋白单克隆抗体 | |
CN101609097B (zh) | Ev71中和抗体的竞争酶联免疫检测方法、试剂盒或试剂及其制备方法 | |
CN101968488A (zh) | 鹅副粘病毒病胶体金快速诊断试纸条 | |
CN102747044B (zh) | 一种抗猪伪狂犬病病毒的杂交瘤细胞系及其制备方法和一种单克隆抗体及其应用 | |
CN105601744A (zh) | 抗甲型流感病毒核蛋白的重组抗体及其制备方法和应用 | |
CN102464716A (zh) | 一种用于猪、人和蚊子中乙型脑炎病毒抗原检测的elisa试剂盒及应用 | |
CN105567643A (zh) | 可分泌抗ev71病毒蛋白vp1单克隆抗体的杂交瘤细胞、单克隆抗体及应用 | |
CN104120109A (zh) | 牛传染性鼻气管炎病毒gB抗体检测阻断ELISA试剂盒及用途 | |
CN101012445A (zh) | 一种鸡禽流感疫苗免疫与病毒野毒感染的胶体金免疫层析快速鉴别诊断试剂盒及应用 | |
CN107177558A (zh) | 分泌口蹄疫病毒共享型单克隆抗体10b10的杂交瘤细胞系及其应用 | |
CN101671655B (zh) | 一种艾滋病毒p24的单克隆抗体杂交瘤细胞及应用 | |
CN102304180A (zh) | 禽网状内皮组织增生症病毒囊膜蛋白的单克隆抗体及其制备方法 | |
CN102286431B (zh) | 抗乙型脑炎病毒的单克隆抗体及其应用 | |
CN104422771A (zh) | 检测蜱传脑炎病毒的单克隆抗体及其试剂盒 | |
CN108148813A (zh) | 一株杂交瘤细胞株及其分泌的抗牛传染性鼻气管炎病毒单克隆抗体和应用 | |
CN102331501A (zh) | IgY-McAb夹心ELISA检测旋毛虫循环抗原的方法 | |
CN106754738A (zh) | 分泌口蹄疫病毒共享型单克隆抗体3d9的杂交瘤细胞系及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20161228 Address after: 518000 Guangdong city of Shenzhen province Nanshan District Xili liuxiandong Zhongshan Road No. 1001 TCL Science Park building D2 building 6 layer ABCD unit 601, 602, 603, 604. Applicant after: Fei Peng Biological Co., Ltd. Applicant after: Guangdong Peng Peng biological Co., Ltd. Address before: 518000 Guangdong city of Shenzhen province Nanshan District Xili liuxiandong Zhongshan Road No. 1001 TCL Science Park building D2 building 6 floor Applicant before: Fei Peng Biological Co., Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |